In the next phase of the Cancer Moonshot, NCI will focus on investing in the development and testing of new modalities, including multi-cancer early detection assays, and fostering diversity in oncology, NCI Acting Director Douglas R. Lowy said at a joint meeting of the Board Of Scientific Advisors and the National Cancer Advisory Board.
I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.
